论文部分内容阅读
耐甲氧西林金黄色葡萄球菌(methicillin-resistantStaphylococcus aurues,MRSA)是医院感染和社区获得性感染的重要病原菌,对多种抗菌药物产生不同程度的耐药,所造成的感染发病率呈逐年攀升态势。万古霉素、替考拉宁是治疗 MRSA 的最有效药物。本研究对从临床各类感染标本中分离的30株 MRSA 进行了万古霉素、替考拉宁分别与利福平联合应用的体外抑菌试验,以期为临床有效的治疗MRSA 感染提供实验室依据。一、材料与方法1.标本:30株 MRSA 来自于临床各类感染标本(无重复
Methicillin-resistant Staphylococcus aurues (MRSA) is an important pathogen of nosocomial infections and community-acquired infections, which cause different degrees of resistance to various antimicrobial agents. The incidence of infections is on the rise year by year . Vancomycin, teicoplanin is the most effective drug for the treatment of MRSA. In this study, 30 strains of MRSA isolated from clinical specimens were tested for in vitro antibacterial activity of vancomycin and teicoplanin in combination with rifampicin respectively, in order to provide a laboratory basis for the clinical treatment of MRSA infection . First, the material and methods 1 specimens: 30 MRSA from various clinical specimens (no duplication